Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: a systematic review and network meta-analysis.

Date publication

juillet 2019

Journal

British journal of clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31269287

Résumé

The comparative efficacy, safety and tolerability of budesonide-MMX and oral mesalamine in active, mild-to-moderate ulcerative colitis (UC) are unclear. We conducted a network meta-analysis to fill this evidence gap.

Mots clés

budesonide-MMX, mesalamine, ulcerative colitis

Référence

Br J Clin Pharmacol. 2019 Jul 3;: